TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

Completed · Phase 1/Phase 2

Conditions studied: Ovarian Neoplasms

In brief

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

Key facts

Study ID

NCT00051948

Run by

Telik

People needed

28

Starts

2003-01-01

Expected to finish

2005-01-01

Last updated by the study team

2011-07-25

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer
• Recurrent ovarian cancer or persistent disease following primary treatment
• At least one, but no more than four, prior chemotherapy regimens (all platinum-containing counted as one)
• At least 18 years of age

You may not qualify if…

• Pregnant or lactating women
• History of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which patient has been disease-free for at least 2 years
• Known leptomeningeal metastases or carcinomatous meningitis
• Having received whole pelvis radiation therapy

Where it is running

• Santa Monica Hematology/Oncology Consultants — Santa Monica, California, United States
• Midwest Cancer Research Group, Inc. — Skokie, Illinois, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• M.D. Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.